Search

Corporate Sponsor Program

EHA Ranking for 2024 is now accessible via this link. "Alone we can do so little; together we can do so much.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more

Practical information

Timelines:Application deadline: August 30, 2024 (15:00 CEST)
Notification of awards: December 2024

When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK

CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC

Workshop 2:
Date:…

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more

EHA-PTHiT Hematology Tutorial on Novel Treatment Approaches in Hematologic Malignancies

EHA in collaboration with the Polish Society for Hematology and Transfusion (PTHiT) have decided to postpone this highly anticipated Hematology Tutorial to a future date, to be announced.

Read more